The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the rapid evolution of non-invasive medical diagnostics, the U.S. FDA has granted approval for Freenome's blood-based colorectal cancer screening test. This diagnostic tool specifically targets older adults, offering a significant alternative to traditional screening methods. According to reports, partner company Abbott plans to lead the commercial rollout, with a scheduled launch in the United States during the fall of 2026.
This regulatory milestone strengthens Abbott's position within the healthcare technology sector, as the partnership with Freenome enables access to advanced diagnostic capabilities. Based on analyst assessments, the approval paves the way for new revenue streams by providing patients with less invasive screening options. This development aligns with a broader industry trend toward adopting early detection solutions based on blood samples.
Regarding stock performance, ABT was priced at $103.1 at the close of July 24, 2026, following a trading range between $101.5 and $104.18. With no immediate healthcare-specific catalysts in the upcoming economic calendar, investors will likely focus on further updates regarding production and distribution timelines ahead of the anticipated launch next year.